Enjoy complimentary customisation on priority with our Enterprise License!
About Cancer Vaccines
Cancer vaccines are biological preparations that stimulate or strengthen a person’s immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer.
Technavio's analysts forecast the global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Vaccine-Approval Process
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Application of Vaccines
08.1 Prophylactic Cancer Vaccines
08.2 Therapeutic Cancer Vaccines
09. Global Prophylactic Cancer Vaccines Market
09.1.1 Market Overview
09.1.2 Market Size and Forecast
10. Global Therapeutic Cancer Vaccines Market
10.1.1 Market Overview
10.1.2 Market Size and Forecast
11. Geographical Segmentation
12. Buying Criteria
13. Key Brand Analysis
13.1 Comparative Study between Gardasil and Cervarix
14. Pipeline Portfolio
14.1.1 Prostvac
14.1.2 Neuvax
14.1.3 Rindopepimut
14.1.4 MVax
14.1.5 DCVax-L
14.1.6 ProstAtak
14.1.7 Talimogene Laherparepvec
14.1.8 IMA901
14.1.9 Imprime PGG
14.1.10 OncoVAX
14.1.11 Lucanix
14.1.12 DCVAC/PCa
15. Market Growth Drivers
16. Drivers and Their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and Their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Analysis 2014
21.2.1 Merck
21.2.2 Dendreon
21.2.3 GlaxoSmithKline
21.3 Other and Future Prominent Vendors
22. Opportunities for Cancer Vaccine Vendors
23. Key Vendor Analysis
23.1 Dendreon
23.1.1 Key Facts
23.1.2 Business Overview
23.1.3 Recent Developments
23.1.4 SWOT Analysis
23.2 GlaxoSmithKline
23.2.1 Key Facts
23.2.2 Business Overview
23.2.3 Business Segmentation by Revenue 2014
23.2.4 Business Segmentation by Revenue 2013 and 2014
23.2.5 Geographical Segmentation by Revenue 2014
23.2.6 Business Strategy
23.2.7 Recent Developments
23.2.8 SWOT Analysis
23.3 Merck
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Business Segmentation by Revenue 2013
23.3.4 Business Segmentation by Revenue 2012 and 2013
23.3.5 Sales by Geography
23.3.6 Business Strategy
23.3.7 Key Developments
23.3.8 SWOT Analysis
24. Other Reports in this Series
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.